TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06460415

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: photobiomidulação
Description: The volunteers in the GFBM group will undergo 8 sessions of a combined red and infrared laser protocol with 4J of infrared power and 4J of red power. Being applied at 8 points (4 red and 4 infrared) in the vulvar region and 8 points (4 red and 4 infrared) points in the intravaginal pelvic floor region. The MMO semiconductor laser device (GaA1As and InGaAlP) will be used with an area of the output laser beam at the NOZZLE of the laser pen of 3mm2 and wavelengths of 660nm (Red Laser) and 808nm (Infrared Laser) with a power of 100mW. The application will be carried out with the volunteers on a stretcher, in the supine position, gynecological position, with the knees and hips flexed and in abduction, feet supported on the stretcher.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo control will be administered using the same device as the GFBM, but without any therapeutic dose delivery. Furthermore, the irradiated sites and irradiation time will be the same as PBMT. Volunteers will receive a total dose of 0 J in placebo mode. This treatment was also carried out in 8 sessions.
Study: NCT04893070

Intervention type: OTHER
Intervention: Questionnaires COVID+
Description: * 1 questionnaire on COVID-19 symptomatology and quality of life 12 months after COVID-19 first symptoms~* 1 questionnaire on quality of life 18 months after COVID-19 first symptoms

Intervention type: OTHER
Intervention: Questionnaires COVID-
Description: * 1 questionnaire on quality of life at enrollment~* 1 questionnaire on quality of life 6 months after enrollment
Study: NCT06078930

Intervention type: DIAGNOSTIC_TEST
Intervention: Tongue imaging, tougue coating, saliva, and feces
Description: Tongue images, coating, saliva, and feces on the tongue and clinical data of patients with gastric cancer and healthy participants will be collected.

Intervention type: DIAGNOSTIC_TEST
Intervention: Tongue imaging, tougue coating, saliva, and feces
Description: Tongue images, coating, saliva, and feces on the tongue and clinical data of patients with gastric cancer and healthy participants will be collected.
Study: NCT04948879

Intervention type: PROCEDURE
Intervention: Vascular resection/reconstruction
Description: The resection of a major blood vessel with or without reconstruction
Study: NCT05921071

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid
Description: One gram of tranexamic acid (Hexakapron) is administered intravenously before surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: patients will receive 10 ml of normal saline 0.9% intravenously.
Study: NCT05592080

Intervention type: RADIATION
Intervention: MRI
Description: MRI-mDIXON-Quant examinations, anthropometric measures, body composition, hormonal and biochemical assays were performed in all participants, and the liver fat fraction (LFF) and muscle fat fraction (MFF) represented the fat content in the liver and skeletal muscle, respectively.

Intervention type: RADIATION
Intervention: MRI
Description: MRI-mDIXON-Quant examinations, anthropometric measures, body composition, hormonal and biochemical assays were performed in all participants, and the liver fat fraction (LFF) and muscle fat fraction (MFF) represented the fat content in the liver and skeletal muscle, respectively.
Study: NCT05581238

Intervention type: OTHER
Intervention: TRACK-TCT
Description: An extra variable will be added to an existing prediction model. It is hypothesized that the predictive ability will improve and that better distinction could be made between patients with an increased risk for receiving blood transfusions.
Study: NCT05047796

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Protocol
Description: The intervention protocol will consist of visceral osteopathic techniques and will be performed by a professional who has 17 years of clinical experience in the field of Osteopathy.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Protocol
Description: The sham protocol will be performed by a professional who has 17 years of clinical experience in the field of Osteopathy. The sham protocol will consist of simulation of therapy, where the therapist will place his hands in the same regions of the intervention protocol, without therapeutic intent
Study: NCT05372887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNX-102 SL
Description: Patients will take 2 tablets of randomly assigned study drug sublingually each day at bedtime starting on Day 1 for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will take 2 tablets of randomly assigned study drug sublingually each day at bedtime starting on Day 1 for 12 weeks
Study: NCT05273086

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Intervention Group
Description: The intervention group will acquire skills to improve their quality of sleep such as:~* Acquisition of notions of chronobiology.~* Location of the nervous structures involved in biological rhythms.~* Awareness of the existence of three times that direct our biological rhythms, and of the need for them to be synchronized.~* Self-knowledge of the chronotype and the degree of adjustment of the three times.~* Knowledge of the variables that determine a good quality of sleep.~* Applications of chronobiology to the field of nursing. Recommendations for nurses and patients.~* Self-knowledge of the quality of sleep and the health status of the circadian system.
Study: NCT05825664

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic resection
Description: Group 1: Polyps are resected by UEMR Group 2: Polyps are resected by CEMR

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic resection
Description: Group 1: Polyps are resected by UEMR Group 2: Polyps are resected by CEMR
Study: NCT05045911

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Barbed-clips Suturing
Description: Endoscopic Barbed-clips Suturing
Study: NCT06099431

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Mandibular marginal resection and reconstruction
Description: Intraoral buccal and lingual incisions 2-3 mm away from the free gingival margins were carried out around the teeth to be included in the resection. The osteotomy lines were marked using a long shank surgical tapered fissure bur. The osteotomies completed and the resected segment was removed.

Intervention type: DEVICE
Group type: OTHER
Intervention: mandibular osteosynthesis a 2.3mm reconstruction bone plate
Description: a 2.3 mm reconstruction bone plate was then fit in place and fixed to both the proximal and distal segments
Study: NCT05347290

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rampart IC, M1128
Description: Rampart IC, M1128 aims to address the challenge of radiation protection in the cardiac catheterization laboratory without the burden of wearing a heavy lead apron. Rampart M1128 is a compactly designed, portable, fully adjustable system that provides radiation protection for interventionalists and their technicians. It has independently adjustable flexible panels, allowing interventionalists multiple vascular access points, including right radial, bi-lateral femoral, and bi-lateral pedal. Participants in this arm will conduct catherization procedures using only the Rampart System, and radiation exposure will be measured using real-time dosimeters.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lead Apron and Ancillary Shield
Description: Participating providers in this arm will use conventional skirt and vest, thyroid collar, and 100% use of 2 types of ancillary shields. Most wrap-around skirts and vests were (0.25-0.5 mm) Pb. Thyroid shields were 0.5 mm Pb equivalent. Under the table lead x 2. Radiation exposure will be measured using real-time dosimeters.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rampart IC, M1128 and Lead Apron
Description: Participating providers will use both the lead apron and the Rampart Shield. Radiation exposure will be measured using real-time dosimeters.
Study: NCT06523543

Intervention type: PROCEDURE
Intervention: Inclusion (Visit 1 - Week 7-16)
Description: Extraction of cervico-vaginal sampling

Intervention type: DIAGNOSTIC_TEST
Intervention: Second semester of pregnancy (Visit 2 - Week 20-24)
Description: Ultrasound examination (determination of chromosomal sex)

Intervention type: DIAGNOSTIC_TEST
Intervention: Third semester of pregnancy (Visit 3- Week 34)
Description: Ultrasound examination (determination of chromosomal sex) if this has not be done during the Visit 2 or if a new determination correcting the previous one is provided.
Study: NCT05173233

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter Annuloplasty
Description: Under echocardiography guidance, the transcatheter tricuspid annuloplasty system precisely reaches the specified position in the tricuspid valve region via jugular vein and superior vena cava approach. The enlarged tricuspid annular tissue is clamped with the clamp cpart and anchor part to reduce the perimeter of tricuspid annulus, so that the area of tricuspid orifice that could not be coapted is reduced. It plays the purpose of minimally invasive treatment of tricuspid valve.
Study: NCT06291740

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous nebulization
Description: continuous nebulization using the MiniHEART-HiFlo® nebulizer containing Budesonide 1000 microgram/2 ml (3 respules) + 1.25 mg of fenoterol and 0.5 mg of ipratropium bromide (Berodual®, 4 ml) and Normal saline 12 ml in the nebulizer chamber. Patients in this group will receive continuous aerosol therapy over a period of 1 hour at an oxygen flow rate of 8 L/min

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent nebulization
Description: intermittent nebulization using a nebulizer containing Budesonide 1000 microgram/2 ml (1 respules) + 1.25 mg of fenoterol and 0.5 mg of ipratropium bromide (Berodual®, 4 ml) at an oxygen flow rate of 10 L/min every 20 minutes, thrice within 1 hour
Study: NCT06131216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-2022 Injection
Description: SHR-2022 Injection is administered by intravenous (IV) infusion
Study: NCT05197205

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nasopharyngeal swabbing
Description: A nasopharyngeal swab is collected during the consultation, with bacteriological analysis. No follow-up visit is required for this study
Study: NCT05674318

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alpha-lactalbumin
Description: Oral assumption of two tabs/day containing Alpha-lactalbumin for 30 days
Study: NCT06290804

Intervention type: OTHER
Group type: OTHER
Intervention: education
Description: Training program on Health Impacts of Sustainable Behaviors and Climate Change

Intervention type: OTHER
Group type: OTHER
Intervention: education
Description: Training program on Health Impacts of Sustainable Behaviors and Climate Change
Study: NCT05897528

Intervention type: OTHER
Intervention: No Intervention
Description: Difference in outcomes in patients with COVID-19 diagnosis and diabetes mellitus groups

Intervention type: OTHER
Intervention: No Intervention
Description: Difference in outcomes in patients with COVID-19 diagnosis and diabetes mellitus groups
Study: NCT05167279

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: JS016/placebo
Description: Two dose groups (300 mg + 1200 mg, and 600 mg + 1200 mg) will be set to receive an intravenous infusion of JS026/placebo + JS016/placebo on Day1. The investigational product and placebo will be distributed in each dose group in a ratio of 3:1.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: JS016/placebo
Description: Two dose groups (300 mg + 1200 mg, and 600 mg + 1200 mg) will be set to receive an intravenous infusion of JS026/placebo + JS016/placebo on Day1. The investigational product and placebo will be distributed in each dose group in a ratio of 3:1.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: JS016/placebo
Description: Two dose groups (300 mg + 1200 mg, and 600 mg + 1200 mg) will be set to receive an intravenous infusion of JS026/placebo + JS016/placebo on Day1. The investigational product and placebo will be distributed in each dose group in a ratio of 3:1.
Study: NCT06158009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: An initial infusion dose of prophylactic norepinephrine (6 ug) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 1 ug of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: An initial infusion dose of prophylactic phenylephrine (75 ug) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 12.5 ug of prophylactic phenylephrine according to the responses of previous patients according to the up-down sequential allocation.
Study: NCT05542394

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: water soluble version of turmeric extract standardized to 10% curcuminoids~.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Curcumin
Description: water soluble version of turmeric extract standardized to 10% curcuminoids~.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Curcumin
Description: water soluble version of turmeric extract standardized to 10% curcuminoids~.
Study: NCT06346171

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Integrative Psychotherapy
Description: Music therapy: Weightless by Marconi Union plays continuously, bridging VR distraction and psychotherapy.~Before: Patients pick a VR scene (-13 to -10 min), learn VR navigation, and practice 4-7-8 breathing with a VR flower for grounding and resilience (-10 to -9 min). They continue 4-7-8 doing Progressive Muscle Relaxation (4+7 contraction, 8 relaxation), moving from lower body to facial muscles (-8 to -5 min). Values and commitment to action are discussed (-4 to -2 min), emphasizing present-focused thoughts and acceptance (-1 min).~During: Mindfulness and relaxation are encouraged, with PMR during intense moments. Empowerment and procedural feedback are provided (0 to 30/45 min).~After: Debriefing normalizes the experience, reinforcing proactive health actions (35 to 50 min).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Virtual Reality Distraction
Description: Software: Nature Treks VR nature environments. Hardware: dedicated head-mounted VR display (Oculus Rift S.) powered by a high-end computer (Laptop with at least GTX 1080 graphics card, both with processing units that lower the bottleneck chances); minimum specifications should facilitate presence while limiting cybersickness by ensuring refresh rates beyound 85 frames/second.~Music therapy: Weightless by Marconi Union plays continuously, facilitating sensorial distraction while also allowing blinding.~Although the psychotherapist will interact with the patient, the dialogue will exclude psychotherapic approaches. The dialogue is designed to be neutral, resembling a comprehensive tutorial for the VR experience. This serves as a comparator to assess the added value of integrating psychotherapeutic techniques within the VR experience.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Distraction
Description: Software: Nature Treks VR nature environments. Hardware: dedicated head-mounted VR display (Oculus Rift S.) powered by a high-end computer (Laptop with at least GTX 1080 graphics card, both with processing units that lower the bottleneck chances); minimum specifications should facilitate presence while limiting cybersickness by ensuring refresh rates beyound 85 frames/second.~Music therapy: Weightless by Marconi Union plays continuously, facilitating sensorial distraction while also allowing blinding.~Although the psychotherapist will interact with the patient, the dialogue will exclude psychotherapic approaches. The dialogue is designed to be neutral, resembling a comprehensive tutorial for the VR experience. This serves as a comparator to assess the added value of integrating psychotherapeutic techniques within the VR experience.
Study: NCT06379568

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT06368882

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peg-Interferon α
Description: Peg IFN-α injection was subcutaneously injected 180 μg weekly on the first day of the first week, and NAs was administered daily according to the standard dosage of each drug. For example, HBsAg sero-conversion is achieved within 48 weeks of treatment, Peg IFNα combined with NAs or PEG-IFNα monotherapy was continued for 12 weeks, with a maximum of 96 weeks, and follow-up up to 240 weeks after treatment. If HBsAg negative sero-conversion is not achieved within 48 weeks of treatment, the maximum duration of PEG-IFNα is not more than 96 weeks. If Peg IFNα combined NAs regimen is used, NAs can be continued until the drug can be ended (if HBsAg negative conversion is achieved, NAs should be ended after consolidation therapy not less than 24 weeks; if HBsAg negative conversion is not achieved, NAS should be continued), followed up to 240 weeks after treatment.
Study: NCT05572372

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: The aim of the intervention was to increase psychological flexibility. Therapeutic methods focused on values clarification, cognitive defusion, self-as-context, acceptance, commited action and flexible attention to present moment.
Study: NCT05628857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC108
Description: RC108 is comprised of an antibody component conjoined to a drug component in a lyophilized powder, which is made into solution for intravenous administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC108
Description: RC108 is comprised of an antibody component conjoined to a drug component in a lyophilized powder, which is made into solution for intravenous administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC108
Description: RC108 is comprised of an antibody component conjoined to a drug component in a lyophilized powder, which is made into solution for intravenous administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC108
Description: RC108 is comprised of an antibody component conjoined to a drug component in a lyophilized powder, which is made into solution for intravenous administration.
Study: NCT05786612

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biatain® Silicone
Description: Wound care dressing

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mepilex Border with Aquacel Extra Hydrofiber
Description: Wound care dressing
Study: NCT05385224

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PillSense
Description: The PillSense System is intended to detect the presence of blood in the stomach for the evaluation of upper gastrointestinal bleeding.
Study: NCT05277350

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SNIPR001
Description: SNIPR001 is a live biotherapeutic product consisting of genetically modified bacteriophages specifically targeting Escherichia coli

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SNIPR001
Description: SNIPR001 is a live biotherapeutic product consisting of genetically modified bacteriophages specifically targeting Escherichia coli

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SNIPR001
Description: SNIPR001 is a live biotherapeutic product consisting of genetically modified bacteriophages specifically targeting Escherichia coli

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT05075044

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated COVID-19 vaccine
Description: three doses of inactivated COVID-19 vaccine
Study: NCT06509672

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined Plyometric and Endurance Training
Description: this include Combined Plyometric and Endurance Training for 12 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plyometric Training
Description: this include Plyometric Training for 12 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endurance training
Description: this include Endurance Training for 12 weeks
Study: NCT04482244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Liquid taken orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Liquid taken orally
Study: NCT05078749

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training group
Description: A regular advanced exercise program will be given and followed.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control training group
Description: Basic exercises will be given at the beginning and will do the same exercises
Study: NCT04153422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panzyga IVIG
Description: Immune Globulin Infusion 10% (Human)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% NaCl prepared as the calculated dose equivalent volume to IVIG.
Study: NCT05917548

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Teledentistry oral health promotion
Description: Educational videos specially designed and validated for elderly (duration 4 to 6 minutes each one)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-Face oral health promotion
Description: Standardized PowerPoint presentation of 15 minutes about the most common or dangerous oral diseases (dental caries, periodontal disease and oral cancer), and toothbrushing and flossing practice in dental models

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face-to-Face oral health promotion
Description: Standardized PowerPoint presentation of 15 minutes about the most common or dangerous oral diseases (dental caries, periodontal disease and oral cancer), and toothbrushing and flossing practice in dental models
Study: NCT06259513

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: omission of SLNB in SentiOMIT or omission of ALND in SentiMACRO
Description: Omission of SLNB in cT1-2N0 or Omission of ALND in patients with \</= 2 macrometastasis in SLNB

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: omission of SLNB in SentiOMIT or omission of ALND in SentiMACRO
Description: Omission of SLNB in cT1-2N0 or Omission of ALND in patients with \</= 2 macrometastasis in SLNB